Mesoblast Limited vs MasTec Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while MasTec Inc trades at $277.54 (market cap $21.90B). The key difference: MasTec Inc is far larger — about 9.9× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| MESO | MTZ | |
|---|---|---|
Market Cap | $2.21B | $21.90B |
Sector | Technology | Technology |
52-Week High | $20.96 | $437.51 |
52-Week Low | $12.88 | $172.51 |
Enterprise Value | $2.21B | $24.81B |
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →